JWH-146

JWH-146 is a analgesic drug used in scientific research, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is an analog of HU-210 which has been substituted with a quinoline group.

Chemistry

JWH-146 is part of the JWH series of synthetic cannabinoids that were created by John W. Huffman for research purposes. The JWH series includes a range of different compounds that vary in their chemical structures and effects. JWH-146 is a derivative of HU-210, which is itself a synthetic cannabinoid. The key difference between JWH-146 and HU-210 is the substitution of a quinoline group in place of the naphthoyl group found in HU-210.

Pharmacology

JWH-146 acts as an agonist at both the CB1 and CB2 cannabinoid receptors. The CB1 receptor is primarily located in the brain and is responsible for the psychoactive effects of cannabinoids. The CB2 receptor is found primarily in the immune system and is thought to be responsible for the anti-inflammatory and other therapeutic effects of cannabinoids.

Uses

JWH-146, like other compounds in the JWH series, is used in scientific research. It is particularly useful for studying the effects of cannabinoids on the brain and immune system, due to its ability to act at both the CB1 and CB2 receptors.

Legal Status

The legal status of JWH-146 varies by country. In some countries, it is classified as a controlled substance due to its similarity to other cannabinoids which are controlled substances.

See Also

• JWH-018
• JWH-073
• JWH-200
• Cannabinoid receptor
• Cannabinoid

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia